Skip to main content

Novo Holdings — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

216
Companies
$15.2B
Total invested
$84.4M
Avg. check
22
Industries
Biotechnology 18Health Care 13Medical 9Biopharma 7Therapeutics 7Life Science 6+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 216
Invetx
May 2022

Invetx is a veterinary therapeutics company that develops protein-based therapeutics for the treatment of various animal diseases.

Biopharma · Boston$60.5M Series B
Route 92 Medical
April 2026

Route 92 Medical is a medical device company developing a catheter to treat stroke.

Health Care · San Mateo$50.0M Private Equity
Coultreon Biopharma
April 2026

CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.

Analytics · Heverlee$125.0M Series A
Ray Therapeutics
April 2026

Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.

Biotechnology · San Diego$125.0M Series B
Spruce Biosciences
April 2026

Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.

Biopharma · South San Francisco$60.0M Post-IPO Equity
Glycomine
April 2025

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

Biotechnology · San Carlos$115.0M Series C
Terremoto Biosciences
April 2026

Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.

Biotechnology · San Francisco$108.0M Series C
ADCendo
April 2026

Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.

Biotechnology · Copenhagen$75.0M Series C
SUBRA A/S
April 2026

SUBRA A/S focuses on innovation, industrial-scale production, and creating a sustainable impact.

Electronics · Farum$46.9M Series A
Supira Medical
March 2025

Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions.

Health Care · Los Gatos$120.0M Series E
Hillstar Bio
March 2025

Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.

Biotechnology · Boston$67.0M Series A
Augustine Therapeutics
March 2025

Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases

Biopharma · Leuven$83.9M Series A
Rondo Therapeutics
March 2022

Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.

Biopharma · Hayward$67.0M Series A
Clasp Therapeutics
March 2024

Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.

Biotechnology · Cambridge$150.0M Series A
Precirix
March 2022

Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.

Biotechnology · Brussels$88.2M Series B
Freeline
March 2022

Freeline is a biotechnology company that develops transformative gene therapies for systemic debilitating diseases.

Biopharma · Stevenage$26.1M Post-IPO Equity
Centauri Therapeutics
February 2026

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.

Biotechnology · Alderley Park$8.1M Series A
Aquafortus
February 2023

Aquafortus is a non-thermal recovery and crystallization technology platform.

Consulting · Mangere$17.0M Series A
Aligos Therapeutics
February 2025

Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.

Biotechnology · San Francisco$105.0M Post-IPO Equity
Hemab
October 2025

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

Biotechnology · Copenhagen$157.0M Series C
Expedition Therapeutics
October 2025

Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.

Biotechnology · San Francisco$165.0M Series A
Nalu Medical
September 2025

Nalu Medical is a medical technology company that offers neurostimulation system designed to treat chronic nerve pain.

Health Care · Carlsbad$50.0M Venture - Series Unknown
Phasecraft
September 2025

Phasecraft develops quantum algorithms and related intellectual property for scientific and industrial applications.

Computer · London$34.0M Series B
MapLight Therapeutics
July 2025

MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.

Biopharma · Palo Alto$372.5M Series D

Where Novo Holdings invests

Biotechnology18
Health Care13
Medical9
Biopharma7
Therapeutics7
Life Science6

About Novo Holdings's portfolio

How many companies has Novo Holdings invested in?

Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Novo Holdings invest in?

Novo Holdings's top investment sectors include Biotechnology, Health Care, Medical, Biopharma, Therapeutics. The firm invests across 22 different industry categories.

What is Novo Holdings's largest investment?

Among tracked funding rounds, MapLight Therapeutics received $372.5M in a Series D round. Novo Holdings's total known invested capital is $15.2B.

What is the average investment size for Novo Holdings?

Novo Holdings's average investment size is $84.4M across its portfolio of 216 companies.

What are Novo Holdings's most recent investments?

Recent Novo Holdings portfolio additions include Invetx, Route 92 Medical, Coultreon Biopharma, Ray Therapeutics, Spruce Biosciences. These companies were founded in 2020 or later.

Reach the founders behind these 216 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →